Medisprof S.R.L. — Clinical Trial Site

53 Registered trials

15 Currently recruiting

Organisation

Medisprof S.R.L.

Location

Cluj-Napoca, Romania

Identifier

ORG-100033873

Address

Bulevardul Muncii Nr. 283, 400641, Romania

Departments

3202: Oncology
3202:oncology
6102: Oncology
6109:Oncology
732: Oncology
93150002: Oncology
Departament Clinic Oncologie Medicala
Department of Medical Oncology
Medical Oncology
N/A
Oncologie
Oncologie medicala
Oncology
ROU003: Oncology
Secţia Oncologie Medicală
Specialitatea Oncologie Generala si Chimioterapie

Clinical trials at this site (53)

Search interface

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending

2025-525013-23-00 Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC) 4
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
Volrustomig Priming Regimens Exploratory Phase II Platform Study Recruiting

2023-509482-20-00 Solid Tumors 4 2024-12-03
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting

2023-503523-25-00 Non-small cell lung cancer 4 2024-02-29
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Non-Small Cell Lung Cancer 5 2025-12-09
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF… Recruiting

2022-502092-33-00 Extensive-disease small cell lung cancer and high SLFN1 4 2024-05-31
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Chemotherapy-induced Thrombocytopenia in Adult subjects 5 2019-11-04
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced… Ended

2022-501483-18-00 Advanced Non-Small Cell Lung Cancer 10 2025-03-28
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr… Ended

2024-513160-25-00 Melanoma and Non-small-cell lung cancer 5 2024-10-30
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26